{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T17:01:12Z","timestamp":1740157272012,"version":"3.37.3"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,20]],"date-time":"2022-05-20T00:00:00Z","timestamp":1653004800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004919","name":"King Abdulaziz City for Science And Technology","doi-asserted-by":"publisher","award":["5-20-01-016-0002"],"award-info":[{"award-number":["5-20-01-016-0002"]}],"id":[{"id":"10.13039\/501100004919","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Saudi Pharmaceutical Journal"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.jsps.2022.05.006","type":"journal-article","created":{"date-parts":[[2022,5,23]],"date-time":"2022-05-23T05:40:29Z","timestamp":1653284429000},"page":"964-970","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["The relationship between hydroxychloroquine plasma concentration and COVID-19 outcomes in rheumatoid arthritis patients in Saudi Arabia"],"prefix":"10.1007","volume":"30","author":[{"given":"Ismail A.","family":"Walbi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hussain","family":"Alqhtani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faleh","family":"Alqahtani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saad Ahmed","family":"Alkahtani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali","family":"Mohamed Alshabi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amer S.","family":"Alali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassan A.","family":"Albarqi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"issue":"2","key":"10.1016\/j.jsps.2022.05.006_b0005","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/jamainternmed.2020.6319","article-title":"Efficacy and safety of hydroxychloroquine vs placebo for pre-exposure SARS-CoV-2 prophylaxis among health care workers: a randomized clinical trial","volume":"181","author":"Abella","year":"2021","journal-title":"JAMA Internal Med."},{"issue":"1","key":"10.1016\/j.jsps.2022.05.006_b0010","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3899\/jrheum.180158","article-title":"Hydroxychloroquine levels throughout pregnancies complicated by rheumatic disease: implications for maternal and neonatal outcomes","volume":"46","author":"Balevic","year":"2019","journal-title":"J. Rheumatol."},{"issue":"1_suppl","key":"10.1016\/j.jsps.2022.05.006_b0015","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/0961203396005001041","article-title":"Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases","volume":"5","author":"Furst","year":"1996","journal-title":"Lupus."},{"issue":"4","key":"10.1016\/j.jsps.2022.05.006_b0020","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1007\/s00253-021-11094-4","article-title":"Chloroquine and hydroxychloroquine in the treatment of COVID-19: the never-ending story","volume":"105","author":"Gasmi","year":"2021","journal-title":"Appl. Microbiol. Biotechnol."},{"issue":"1","key":"10.1016\/j.jsps.2022.05.006_b0025","doi-asserted-by":"crossref","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","volume":"56","author":"Gautret","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.jsps.2022.05.006_b0030","doi-asserted-by":"crossref","first-page":"101663","DOI":"10.1016\/j.tmaid.2020.101663","article-title":"Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study","volume":"34","author":"Gautret","year":"2020","journal-title":"Travel Med. Infect. Dis."},{"issue":"1","key":"10.1016\/j.jsps.2022.05.006_b0035","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-021-05758-9","article-title":"Pre-exposure prophylaxis with hydroxychloroquine for COVID-19: a double-blind, placebo-controlled randomized clinical trial","volume":"22","author":"Grau-Pujol","year":"2021","journal-title":"Trials."},{"issue":"10223","key":"10.1016\/j.jsps.2022.05.006_b0040","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan","volume":"395","author":"Huang","year":"2020","journal-title":"China. The lancet."},{"key":"10.1016\/j.jsps.2022.05.006_b0045","unstructured":"int, C.W., 2020. WHO coronavirus disease (COVID-19) dashboard."},{"issue":"4","key":"10.1016\/j.jsps.2022.05.006_b0050","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.cmi.2020.12.003","article-title":"Effect of hydroxychloroquine pre-exposure on infection with SARS-CoV-2 in rheumatic disease patients: a population-based cohort study","volume":"27","author":"Jung","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"issue":"30","key":"10.1016\/j.jsps.2022.05.006_b0055","doi-asserted-by":"crossref","first-page":"40431","DOI":"10.1007\/s11356-020-12200-1","article-title":"Hydroxychloroquine in COVID-19: therapeutic promises, current status, and environmental implications","volume":"28","author":"Kumar","year":"2021","journal-title":"Environ. Sci. Pollut. Res."},{"key":"10.1016\/j.jsps.2022.05.006_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.tmaid.2020.101791","article-title":"Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine\/azithromycin and other regimens in Marseille, France: A retrospective analysis","volume":"36","author":"Lagier","year":"2020","journal-title":"Travel Med. Infect. Dis."},{"issue":"1","key":"10.1016\/j.jsps.2022.05.006_b0065","doi-asserted-by":"crossref","DOI":"10.1038\/s41421-020-0156-0","article-title":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro","volume":"6","author":"Liu","year":"2020","journal-title":"Cell Discovery"},{"issue":"9","key":"10.1016\/j.jsps.2022.05.006_b0070","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/acr.22837","article-title":"Hydroxychloroquine serum concentrations and flares of systemic lupus erythematosus: a longitudinal cohort analysis","volume":"68","author":"Mok","year":"2016","journal-title":"Arthritis Care Res."},{"year":"2020","series-title":"Hydroxychloroquine and chloroquine for treatment of SARS-CoV-2 (COVID-19). Open forum infectious diseases","author":"Pastick","key":"10.1016\/j.jsps.2022.05.006_b0075"},{"issue":"5","key":"10.1016\/j.jsps.2022.05.006_b0080","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s10787-015-0239-y","article-title":"Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases","volume":"23","author":"Rainsford","year":"2015","journal-title":"Inflammopharmacology."},{"issue":"11","key":"10.1016\/j.jsps.2022.05.006_b0085","doi-asserted-by":"crossref","first-page":"e835","DOI":"10.1093\/cid\/ciaa1571","article-title":"Hydroxychloroquine as pre-exposure prophylaxis for coronavirus disease 2019 (COVID-19) in healthcare workers: a randomized trial","volume":"72","author":"Rajasingham","year":"2021","journal-title":"Clin. Infect. Dis."},{"issue":"1","key":"10.1016\/j.jsps.2022.05.006_b0090","doi-asserted-by":"crossref","first-page":"e19","DOI":"10.1016\/S2665-9913(20)30378-7","article-title":"Effect of pre-exposure use of hydroxychloroquine on COVID-19 mortality: a population-based cohort study in patients with rheumatoid arthritis or systemic lupus erythematosus using the OpenSAFELY platform","volume":"3","author":"Rentsch","year":"2021","journal-title":"The Lancet Rheumatol."},{"issue":"24","key":"10.1016\/j.jsps.2022.05.006_b0095","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1001\/jama.2020.8630","article-title":"Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York State","volume":"323","author":"Rosenberg","year":"2020","journal-title":"JAMA."},{"issue":"10","key":"10.1016\/j.jsps.2022.05.006_b0100","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1001\/jamainternmed.2020.2594","article-title":"US hydroxychloroquine, chloroquine, and azithromycin outpatient prescription trends, October 2019 through March 2020","volume":"180","author":"Shehab","year":"2020","journal-title":"JAMA Internal Med."},{"issue":"2","key":"10.1016\/j.jsps.2022.05.006_b0105","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1002\/ame2.12065","article-title":"Protective effect of hydroxychloroquine on rheumatoid arthritis-associated atherosclerosis","volume":"2","author":"Shi","year":"2019","journal-title":"Animal Models Exp. Med."},{"key":"10.1016\/j.jsps.2022.05.006_b0110","article-title":"Chloroquine and hydroxychloroquine toxicity","author":"Stokkermans","year":"2021","journal-title":"StatPearls [Internet]."},{"issue":"6","key":"10.1016\/j.jsps.2022.05.006_b0115","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/j.1365-2125.1989.tb03439.x","article-title":"Bioavailability of hydroxychloroquine tablets in healthy volunteers","volume":"27","author":"Tett","year":"1989","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.jsps.2022.05.006_b0120","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41590-020-00816-x","article-title":"The immunology of rheumatoid arthritis","volume":"22","author":"Weyand","year":"2021","journal-title":"Nat. Immunol."},{"issue":"5","key":"10.1016\/j.jsps.2022.05.006_b0125","doi-asserted-by":"crossref","first-page":"702","DOI":"10.2215\/CJN.11781017","article-title":"Hydroxychloroquine use and risk of CKD in patients with rheumatoid arthritis","volume":"13","author":"Wu","year":"2018","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"15","key":"10.1016\/j.jsps.2022.05.006_b0130","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1093\/cid\/ciaa237","article-title":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","volume":"71","author":"Yao","year":"2020","journal-title":"Clin. Infect. Dis."}],"container-title":["Saudi Pharmaceutical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1319016422001347?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1319016422001347?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,6]],"date-time":"2025-01-06T17:28:09Z","timestamp":1736184489000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1319016422001347"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":26,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S1319016422001347"],"URL":"https:\/\/doi.org\/10.1016\/j.jsps.2022.05.006","relation":{},"ISSN":["1319-0164"],"issn-type":[{"type":"print","value":"1319-0164"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The relationship between hydroxychloroquine plasma concentration and COVID-19 outcomes in rheumatoid arthritis patients in Saudi Arabia","name":"articletitle","label":"Article Title"},{"value":"Saudi Pharmaceutical Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jsps.2022.05.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier B.V. on behalf of King Saud University.","name":"copyright","label":"Copyright"}]}}